Fluotek is a pioneer in breakthrough biotechnologies focusing on changing the global healthcare landscape. Unlike other pharmaceutical or diagnostic organizations, the combination of biotherapeutics and diagnostics under one brand offers Fluotek a more complete perspective when tackling the current medical problems. We define ourselves as a leader on the frontier of translating top technologies into therapeutic and diagnostic products. The core pipeline spans the spectrum of regenerative medicine, oncology, immunology, metabolic syndrome, blood-testing, and various medical devices, all of which come from our R&D center with the world-leading platforms and instruments. Since 2016, Fluotek continues to explore better ways to diagnose, treat, cure, and ultimately prevent diseases. Fluotek's achievements are inseparable from our elite employees who dedicated their careers to helping lives, no matter their backgrounds and positions. Our current and future commercialized products and services will make lives better, and this common goal will guide us to rapidly becoming a world leader in the healthcare industry.
| Website | https://www.fluotek.com |
| Revenue | $116.9 million |
| Employees | 27 (23 on RocketReach) |
| Founded | 2016 |
| Technologies | |
| Industry | Biotechnology Research |
| Keywords | Biotechnology, Healthcare, Biotherapeutics, Global Health, Medical Technology, Life Sciences, Health Innovation, Breakthrough Technology, Pharmaceutical, Biomedical, Disease Diagnostics, Clinical Diagnostics, Medical Diagnostics, Drug Discovery, Therapeutics, Precision Medicine, Biomarker Discovery, New Therapies |
| Competitors | Ufluid, Hawkes Learning, EnviroCare International Inc., Aquatech, Hydrotech, Inc., Xylem, AquaVenture Holdings, ADI® Systems, an Evoqua brand, Trojan Technologies, Pentair +26 more (view full list) |
Looking for a particular Fluotek employee's phone or email?
The Fluotek annual revenue was $116.9 million in 2026.
Yang Yang is the CEO of Fluotek.
23 people are employed at Fluotek.